Jonathan Christodoro - Hologic Independent Director
| HOLX Stock | USD 75.77 0.86 1.12% |
Director
Mr. Jonathan Christodoro is Independent Director of the company. Mr. Christodoro joined our Board in December 2013. Mr. Christodoro has served as a Managing Director of Icahn Capital LP the entity through which Carl C. Icahn manages investment funds since July 2012. He is responsible for identifying analyzing and monitoring investment opportunities and portfolio companies for Icahn Capital. Prior to joining Icahn Capital LP Mr. Christodoro served in various investment and research roles at P2 Capital Partners LLC Prentice Capital Management LP and S.A.C Capital Advisors LP. Mr. Christodoro began his career as an investment banking analyst at Morgan Stanley where he focused on merger and acquisition transactions across a variety of industries. Mr. Christodoro also serves on the boards of directors of PayPal Holdings Inc. Cheniere Energy Inc. Herbalife Ltd. American Railcar Industries Inc. and Enzon Pharmaceuticals Inc. . Mr. Christodoro serves as the Chairman of Enzon on the Nominating and Governance Committees of Herbalife and Cheniere and on the Compensation Committees of Herbalife and American Railcar. Carl C. Icahn has a noncontrolling interest in all of these companies through the ownership of securities. Mr. Christodoro also served as a director of Talisman Energy Inc. from December 2013 to May 2015 and eBay Inc. from January to July 2015. Mr. Christodoro received an M.B.A from the University of Pennsylvanias Wharton School of Business with Distinction majoring in Finance and Entrepreneurial Management. He received a B.S. in Applied Economics and Management Magna Cum Laude with Honors Distinction in Research from Cornell University. He also served in the United States Marine Corporationration. Mr. Christodoro was selected as a member of the Board pursuant to the Standstill Agreement with the Icahn Group. since 2013.
| Age | 38 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Address | 250 Campus Drive, Marlborough, MA, United States, 01752 |
| Phone | 508 263 2900 |
| Web | https://www.hologic.com |
Hologic Management Efficiency
The company has return on total asset (ROA) of 0.0649 % which means that it generated a profit of $0.0649 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1057 %, meaning that it created $0.1057 on every $100 dollars invested by stockholders. Hologic's management efficiency ratios could be used to measure how well Hologic manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Hologic's Return On Tangible Assets are fairly stable compared to the past year. Return On Equity is likely to rise to 0.09 in 2024, whereas Return On Capital Employed is likely to drop 0.08 in 2024. At this time, Hologic's Asset Turnover is fairly stable compared to the past year.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Dennis | HCA Holdings | 67 | |
| William Frist | HCA Holdings | 51 | |
| Hartley Rogers | Acadia Healthcare | 56 | |
| NancyAnn DeParle | HCA Holdings | 64 | |
| Wayne Riley | HCA Holdings | 61 | |
| Charles Holliday | HCA Holdings | 73 | |
| EPerot Bissell | Acadia Healthcare | 58 | |
| Wade Miquelon | Acadia Healthcare | 53 | |
| Annie Lamont | HCA Holdings | 60 | |
| Vicky Gregg | Acadia Healthcare | 63 | |
| William Grieco | Acadia Healthcare | 64 | |
| Reeve Waud | Acadia Healthcare | 54 | |
| William Petrie | Acadia Healthcare | 71 | |
| Kyle Lattner | Acadia Healthcare | 29 | |
| Ann Lamont | HCA Holdings | 58 | |
| Michael Michelson | HCA Holdings | 69 | |
| Meg Crofton | HCA Holdings | 67 | |
| Jay Light | HCA Holdings | 74 | |
| Michael Gaynor | Novo Integrated Sciences | 49 | |
| Geoffrey Meyers | HCA Holdings | 73 | |
| John Rowe | HCA Holdings | 72 | |
Management Performance
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0649 |
Hologic Leadership Team
Elected by the shareholders, the Hologic's board of directors comprises two types of representatives: Hologic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hologic. The board's role is to monitor Hologic's management team and ensure that shareholders' interests are well served. Hologic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hologic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wayne Wilson, Independent Director | ||
| Namal Nawana, Director | ||
| Peter Dunne, Senior Resources | ||
| Sally Crawford, Independent Director | ||
| Erik Anderson, Division Solutions | ||
| Mark Irving, VP Secretary | ||
| Jay Stein, Co-Founder, Chairman Emeritus, Chief Technical Officer and Sr. VP | ||
| Stephen MacMillan, Chairman, CEO and Pres | ||
| Sanjay Prabhakaran, Regional President - Asia | ||
| Claus Egstrand, Senior Vice President General Manager - International | ||
| Ludwig Hantson, Director | ||
| Jennifer Schneiders, President Solutions | ||
| Samuel Merksamer, Independent Director | ||
| Christiana Stamoulis, Director and Member of Corporate Devel. Committee | ||
| Robert McMahon, CFO | ||
| Essex Mitchell, Chief Officer | ||
| Jan Verstreken, Regional President - Europe,Middle EastandAfrica(EMEA) and Canada | ||
| Karleen Oberton, CFO, Chief Accounting Officer | ||
| Monica Berthelot, VP Staff | ||
| Thomas West, Division President of Diagnostics Solutions | ||
| Eric Compton, COO | ||
| Paul Malenchini, Chief Officer | ||
| Lawrence Levy, Independent Director | ||
| Benjamin Cohn, Principal Chief Accounting Officer | ||
| Elaine Ullian, Independent Director | ||
| Kevin Thornal, Group Solutions | ||
| Amy Wendell, Director | ||
| Scott Garrett, Independent Director | ||
| Peter Valenti, Division President- Breast and Skeletal Health | ||
| Nancy Leaming, Independent Director | ||
| Scott Christensen, Quality Chain | ||
| Elisabeth Hellmann, Sr Communications | ||
| John Griffin, General Counsel | ||
| Allison Bebo, Senior Vice President - Human Resources | ||
| Mike Kelly, Chief Affairs | ||
| Charles Dockendorff, Director | ||
| Michael Watts, Vice President IR Contact Officer | ||
| Ryan Simon, Vice Relations | ||
| Jonathan Christodoro, Independent Director | ||
| Al Kildani, Senior Director - Investor Relations | ||
| Brandon Schnittker, Division Solutions |
Hologic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hologic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0649 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 18.63 B | ||||
| Shares Outstanding | 234.73 M | ||||
| Shares Owned By Insiders | 0.73 % | ||||
| Shares Owned By Institutions | 99.00 % | ||||
| Number Of Shares Shorted | 4.52 M | ||||
| Price To Earning | 10.21 X |
Hologic Investors Sentiment
The influence of Hologic's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Hologic. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Hologic's public news can be used to forecast risks associated with an investment in Hologic. The trend in average sentiment can be used to explain how an investor holding Hologic can time the market purely based on public headlines and social activities around Hologic. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Hologic's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Hologic's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Hologic's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Hologic.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hologic in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hologic's short interest history, or implied volatility extrapolated from Hologic options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hologic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Hologic Stock please use our How to Invest in Hologic guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Hologic Stock analysis
When running Hologic's price analysis, check to measure Hologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hologic is operating at the current time. Most of Hologic's value examination focuses on studying past and present price action to predict the probability of Hologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hologic's price. Additionally, you may evaluate how the addition of Hologic to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Hologic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hologic. If investors know Hologic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hologic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.373 | Earnings Share 2.11 | Revenue Per Share 16.228 | Quarterly Revenue Growth (0.06) | Return On Assets 0.0649 |
The market value of Hologic is measured differently than its book value, which is the value of Hologic that is recorded on the company's balance sheet. Investors also form their own opinion of Hologic's value that differs from its market value or its book value, called intrinsic value, which is Hologic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hologic's market value can be influenced by many factors that don't directly affect Hologic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hologic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hologic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hologic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.